Orexin A Ameliorates Ovarian Dysfunction in Premature Ovarian Insufficiency Mice by Inhibiting Granulosa Cell...

Area of Science:

• Reproductive Biology
• Endocrinology
• Cellular Biology

Background:

• Premature ovarian insufficiency (POI) involves early ovarian follicle depletion, causing infertility and systemic issues.
• Granulosa cell (GC) pyroptosis is a key factor in POI development.
• Orexin A, a neuropeptide with anti-inflammatory properties, is explored for its therapeutic potential in POI.

Purpose of the Study:

• To investigate the protective effects of Orexin A on ovarian granulosa cells in premature ovarian insufficiency (POI).
• To determine if Orexin A can inhibit pyroptosis and its underlying mechanisms in POI.

Main Methods:

• Utilized a mouse model of POI and cyclophosphamide (CTX)-treated KGN cells (ovarian granulosa cell line).
• Assessed the impact of Orexin A on oxidative stress, NLRP3 inflammasome activation, serum hormone levels, and follicle count.
• Analyzed the expression of NLRP3, caspase-1, and gasdermin D (GSDMD) following Orexin A treatment.
• Investigated the role of adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling pathway.

Main Results:

• Orexin A significantly reduced oxidative stress and NLRP3 inflammasome activation in POI mice.
• Orexin A treatment improved serum hormone levels and ovarian follicle count in POI mice.
• Orexin A inhibited pyroptosis in CTX-treated KGN cells by downregulating NLRP3, caspase-1, and GSDMD.
• These protective effects were linked to the activation of the AMPK signaling pathway.

Conclusions:

• Orexin A demonstrates potential therapeutic benefits for premature ovarian insufficiency (POI).
• Orexin A alleviates POI by inhibiting NLRP3 inflammasome-mediated pyroptosis in granulosa cells.
• Activation of AMPK signaling is a key mechanism through which Orexin A exerts its protective effects in POI.